Neoleukin Therapeutics Inc. (NASDAQ: NLTX) started the day on January 08, 2021, with a price decrease of -10.96% at $14.05. During the day, the stock rose to $14.34 and sunk to $12.35 before settling in for the price of $15.78 at the close. Taking a more long-term approach, NLTX posted a 52-week range of $5.81-$18.13.
Meanwhile, its Annual Earning per share during the time was 1.30%. Nevertheless, stock’s Earnings Per Share (EPS) this year is -91.30%. This publicly-traded company’s shares outstanding now amounts to $54.12 million, simultaneously with a float of $33.39 million. The organization now has a market capitalization sitting at $661.05 million. At the time of writing, stock’s 50-day Moving Average stood at $12.49, while the 200-day Moving Average is $12.47.
Neoleukin Therapeutics Inc. (NLTX) Ownership Facts and Figures
Now let’s turn our focus to how large-scale investors are working with this stock of the Drug Manufacturers – Specialty & Generic Industry. Neoleukin Therapeutics Inc.’s current insider ownership accounts for 20.29%, in contrast to 66.30% institutional ownership. According to the most recent insider trade that took place on Jul 07, this organization’s Director bought 424,000 shares at the rate of 15.25, making the entire transaction reach 6,466,000 in total value, affecting insider ownership by 3,501,691. Preceding that transaction, on Apr 02, Company’s 10% Owner bought 39,300 for 11.37, making the whole transaction’s value amount to 446,958. This particular insider is now the holder of 4,051,045 in total.
Neoleukin Therapeutics Inc. (NLTX) Earnings and Revenue Records
In the latest quarterly report released, which was put into the public domain on 9/29/2020, the organization reported -$0.04 earnings per share (EPS) for the three months, surpassing the consensus estimate (set at -$0.22) by $0.18. This company achieved a return on equity of -64.79. Wall Street market experts anticipate that the next fiscal year will bring earnings of -0.21 per share during the current fiscal year.
Neoleukin Therapeutics Inc.’s EPS decrease for this current 12-month fiscal period is -91.30% and is forecasted to reach -1.00 in the upcoming year. Considering the longer run, market analysts have predicted that Company’s EPS will increase by 31.10% through the next 5 years, which can be compared against the 1.30% growth it accomplished over the previous five years trading on the market.
Neoleukin Therapeutics Inc. (NASDAQ: NLTX) Trading Performance Indicators
Let’s observe the current performance indicators for Neoleukin Therapeutics Inc. (NLTX). It’s Quick Ratio in the last reported quarter now stands at 20.90. The Stock has managed to achieve an average true range (ATR) of 1.47.
In the same vein, NLTX’s Diluted EPS (Earnings per Share) trailing twelve months is recorded -0.65, a figure that is expected to reach -0.24 in the next quarter, and analysts are predicting that it will be -1.00 at the market close of one year from today.
Technical Analysis of Neoleukin Therapeutics Inc. (NLTX)
If we take a close look at the recent performances of Neoleukin Therapeutics Inc. (NASDAQ: NLTX), its last 5-days Average volume was 0.5 million that shows progress from its year to date volume of 0.5 million. During the previous 9 days, stock’s Stochastic %D was recorded 56.79% While, its Average True Range was 1.62.
Raw Stochastic average of Neoleukin Therapeutics Inc. (NLTX) in the period of the previous 100 days is set at 50.51%, which indicates a major rise in contrast to 46.79% during the last 2-weeks. If we go through the volatility metrics of the stock, In the past 14-days, Company’s historic volatility was 148.28% that was higher than 79.85% volatility it exhibited in the past 100-days period.